Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyManagement of HBV and HBV/HDV-Associated Liver CirrhosisKASL clinical practice guidelines: management of chronic hepatitis BHepatocellular carcinoma and hepatitis B surface proteinPotential mechanisms of hepatitis B virus induced liver injuryNew virologic tools for management of chronic hepatitis B and CPrediction models of hepatocellular carcinoma development in chronic hepatitis B patientsDiagnosis of hepatitis BPersonalized health care beyond oncology: new indications for immunoassay-based companion diagnosticsOptimization therapy for the treatment of chronic hepatitis BFavorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG.Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patientsArtificial neural network accurately predicts hepatitis B surface antigen seroclearance.Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Risk stratification of HBV infection in Asia-Pacific region.Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impactHigh hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels.Negative interference in serum HBsAg ELISA from rheumatoid factors.Serum hepatitis B surface antigen titer and transient elastography in screening for insignificant fibrosis in HBeAg-positive chronic hepatitis B patients.Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.Search for a cure for chronic hepatitis B infection: How close are we?Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice.HBsAg level and hepatitis B viral load correlation with focus on pregnancyDurability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis BPlatelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors.Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients.Chronic hepatitis B: what should be the goal for new therapies?Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2aClinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy.Comparing HBV Viral Load in Serum, Cerumen, and Saliva and Correlation With HBeAg Serum Status in Patients With Chronic Hepatitis B InfectionPredictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysisDose-response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and womenRisk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.
P2860
Q26740161-170049A8-1753-40E7-BDEC-1ED245614879Q26740323-C59B47DC-2182-4C1F-BC4C-428E1133E278Q26752475-48CFE5CC-C22D-4232-9324-AA94C8F9F54FQ26766123-C7A87DEA-D90E-4935-8874-1431212C634BQ27014079-28BF67A7-EA95-42E4-A60D-B579AA87C8F8Q27026914-BDC5F2FE-782F-4FAD-9004-BEDA91F46904Q28066959-2F59D42C-5390-49E2-B5E5-3CB7CE4A0647Q28071817-7963A38C-2FB1-48B2-838B-CB57F2B89BBBQ28084590-FEE16BB7-2778-47C6-8FE1-71C532C3DF78Q33626813-34CF87C9-01BC-48FC-9463-02516229FC56Q33694522-CA8F82D5-02D9-4B0E-A589-F01BA1F69A7EQ33695646-34685EA0-59E7-4D9E-9DF8-AE0EB18EC37AQ33734215-DADF1B05-161F-4AAE-AAF5-2399D6DF2566Q33845546-BAC16BF0-9985-4E91-8837-98DDA75878E7Q34339577-002AC2E4-12CF-4026-95F8-4D0843171A9DQ34384793-0796052F-6A2F-4ACF-BACD-AC1A76C36E61Q34387363-9CA30813-814F-4D4E-9140-ECE9B1607F67Q34391308-75DA9FC0-D53A-462E-B9D7-38CBC0168535Q34592952-30DE1CDD-3AA1-4304-9DEC-01B6801312E7Q34598267-6BDF648B-6C62-4406-857E-2D715E15051FQ34764269-53A14A49-ACCE-464D-A0F5-FD60789D3901Q35049168-6FEF82D8-7890-4025-AED2-64090B7F424DQ35105157-2277B8D7-94DA-4C6C-B3ED-E72E20190A41Q35250340-65524942-3F59-4B97-9FEA-862730078AD6Q35473087-0F954A97-6377-4ED8-8192-D06D8A78E43CQ35626790-D8441305-6813-495D-89DA-D72256EF33A5Q35750696-53107BD1-F15E-44EA-8EC1-C1EFA04CDEF9Q35779493-B93F0FAB-EE6A-4E0D-AD6A-A69B452B1F79Q36195218-25832E9A-C077-485C-82F7-17B7C071D185Q36240894-538475CC-B778-4B88-A61F-BFCEB0A7F714Q36254363-76A51527-229A-4C48-ACA6-5AC60DD6B578Q36365030-E73A6358-4959-4165-92A7-7020D957CD58Q36769986-D5FB8041-80B7-4784-BF2D-A9D0DE24005CQ36924978-77830F20-5E82-4333-9306-38E679BD364CQ36973383-0F4B00AE-BA3F-4EFC-8D32-9BDCF475D947Q37001173-95B317FC-9E78-4B35-B165-5706BDA679E7Q37006228-8576A421-C7F3-4F2E-B912-655A2124794BQ37087279-55258E10-0937-4DA4-9422-DF4B5EDC3D79Q37176658-AA2CC0D9-18E3-4274-A2B5-EA5AF7ABE08BQ37241565-5C38E8F9-B47D-45B9-9CE3-44ECC2425DD3
P2860
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis B surface antigen qu ...... in 2011 - a core group report.
@en
Hepatitis B surface antigen qu ...... in 2011 - a core group report.
@nl
type
label
Hepatitis B surface antigen qu ...... in 2011 - a core group report.
@en
Hepatitis B surface antigen qu ...... in 2011 - a core group report.
@nl
prefLabel
Hepatitis B surface antigen qu ...... in 2011 - a core group report.
@en
Hepatitis B surface antigen qu ...... in 2011 - a core group report.
@nl
P2093
P50
P1476
Hepatitis B surface antigen qu ...... in 2011 - a core group report.
@en
P2093
Alex Thompson
Hans L Tillmann
Harry L A Janssen
Heiner Wedemeyer
Ji-Dong Jia
Markus Cornberg
Michelle Martinot-Peignoux
Patrick Marcellin
Stephen Locarnini
Teerha Piratvisuth
P304
P356
10.1016/J.JHEP.2011.06.006
P577
2011-06-28T00:00:00Z